CAN affects up to 50% of diabetic patients and is a strong independent predictor of cardiovascular mortality. VitalScan ANS+ detects autonomic dysfunction through standardized heart rate variability and autonomic reflex testing — identifying at-risk patients before clinical signs appear.

Cardiac Autonomic Neuropathy (CAN) is a serious complication of diabetes that damages the autonomic nerves innervating the heart. It is associated with silent ischemia, arrhythmias, orthostatic hypotension, and significantly increased mortality. Despite its severity, CAN is frequently undiagnosed because it is asymptomatic in early stages. Standardized ANS testing enables early detection when interventions are most effective.
95921–95924Autonomic nervous system function testing93922–93971Vascular studies for cardiovascular assessmentEstimated monthly revenue
3 tests/day × ~$200 avg = $12,000/month
Based on 3 tests per day, 20 working days per month. Actual reimbursement varies by payer and region.
Non-invasive, automated, and reproducible. The entire assessment fits into a single patient visit — no special prep, no dedicated technician required.
Get a personalized ROI analysis with clinical workflow, CPT billing guidance, and financing options — including Section 179 and grant pathways.